 Christopher Raeburn
Concepts (369)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 14 | 2024 | 309 | 2.150 |
Why?
| | Neuroendocrine Tumors | 2 | 2022 | 97 | 0.910 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2024 | 955 | 0.820 |
Why?
| | Reoperation | 2 | 2024 | 541 | 0.810 |
Why?
| | Thyroidectomy | 7 | 2024 | 86 | 0.730 |
Why?
| | Pancreatic Neoplasms | 3 | 2022 | 873 | 0.600 |
Why?
| | Thyroid Carcinoma, Anaplastic | 4 | 2022 | 35 | 0.590 |
Why?
| | Myocardial Ischemia | 3 | 2011 | 247 | 0.550 |
Why?
| | Heart | 4 | 2004 | 637 | 0.500 |
Why?
| | Intercellular Adhesion Molecule-1 | 5 | 2011 | 133 | 0.460 |
Why?
| | Lipopolysaccharides | 6 | 2002 | 854 | 0.450 |
Why?
| | Ischemic Preconditioning | 3 | 2004 | 40 | 0.450 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 3 | 2002 | 37 | 0.440 |
Why?
| | Tumor Necrosis Factor-alpha | 8 | 2010 | 1185 | 0.390 |
Why?
| | Diiodothyronines | 1 | 2011 | 2 | 0.370 |
Why?
| | Propionates | 1 | 2011 | 34 | 0.360 |
Why?
| | Neutrophils | 8 | 2011 | 1192 | 0.360 |
Why?
| | Myocarditis | 1 | 2011 | 98 | 0.330 |
Why?
| | Technetium Tc 99m Sestamibi | 3 | 2015 | 12 | 0.330 |
Why?
| | Parathyroid Glands | 3 | 2015 | 9 | 0.330 |
Why?
| | Ischemic Preconditioning, Myocardial | 4 | 2010 | 28 | 0.330 |
Why?
| | Delirium | 4 | 2014 | 78 | 0.330 |
Why?
| | Myocardium | 6 | 2011 | 967 | 0.330 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2021 | 212 | 0.320 |
Why?
| | Surgical Procedures, Operative | 2 | 2002 | 243 | 0.320 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2016 | 226 | 0.300 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 198 | 0.300 |
Why?
| | Receptors, Tumor Necrosis Factor | 3 | 2003 | 160 | 0.290 |
Why?
| | Shock, Hemorrhagic | 4 | 2004 | 165 | 0.280 |
Why?
| | Postoperative Complications | 9 | 2023 | 2456 | 0.280 |
Why?
| | Adrenocortical Carcinoma | 2 | 2018 | 63 | 0.280 |
Why?
| | Neck Dissection | 2 | 2024 | 15 | 0.260 |
Why?
| | Receptors, Cell Surface | 3 | 2004 | 373 | 0.260 |
Why?
| | Biomarkers, Tumor | 5 | 2024 | 1175 | 0.250 |
Why?
| | Radionuclide Imaging | 3 | 2013 | 121 | 0.250 |
Why?
| | Myocardial Infarction | 2 | 2011 | 1013 | 0.250 |
Why?
| | Antigens, CD | 3 | 2003 | 481 | 0.250 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2021 | 83 | 0.230 |
Why?
| | Recurrent Laryngeal Nerve Injuries | 1 | 2024 | 12 | 0.230 |
Why?
| | Thyroglobulin | 1 | 2024 | 26 | 0.230 |
Why?
| | Hypocalcemia | 2 | 2015 | 28 | 0.220 |
Why?
| | Iodine Radioisotopes | 4 | 2022 | 142 | 0.220 |
Why?
| | Carcinoma, Neuroendocrine | 3 | 2022 | 32 | 0.220 |
Why?
| | Drosophila Proteins | 2 | 2002 | 187 | 0.210 |
Why?
| | Lymph Node Excision | 1 | 2024 | 164 | 0.210 |
Why?
| | Thyroid Nodule | 1 | 2024 | 55 | 0.210 |
Why?
| | Endotoxemia | 2 | 2010 | 82 | 0.210 |
Why?
| | Osteitis Fibrosa Cystica | 1 | 2002 | 1 | 0.210 |
Why?
| | Hyperparathyroidism | 1 | 2002 | 11 | 0.210 |
Why?
| | Thyroxine | 1 | 2023 | 62 | 0.200 |
Why?
| | Humans | 48 | 2024 | 128019 | 0.200 |
Why?
| | Membrane Glycoproteins | 2 | 2002 | 467 | 0.200 |
Why?
| | Pheochromocytoma | 2 | 2021 | 57 | 0.200 |
Why?
| | Hypothyroidism | 1 | 2023 | 70 | 0.200 |
Why?
| | Thoracic Surgery | 1 | 2004 | 122 | 0.200 |
Why?
| | Iodine | 1 | 2022 | 24 | 0.200 |
Why?
| | Prognosis | 5 | 2024 | 3766 | 0.200 |
Why?
| | Neutrophil Infiltration | 1 | 2002 | 103 | 0.190 |
Why?
| | Adenocarcinoma | 2 | 2022 | 888 | 0.190 |
Why?
| | Compartment Syndromes | 1 | 2001 | 22 | 0.190 |
Why?
| | Chemokines | 4 | 2011 | 221 | 0.190 |
Why?
| | Abdomen | 1 | 2001 | 116 | 0.180 |
Why?
| | Regeneration | 1 | 2002 | 174 | 0.180 |
Why?
| | Multiple Trauma | 1 | 2001 | 101 | 0.180 |
Why?
| | Interleukin-18 | 1 | 2002 | 236 | 0.180 |
Why?
| | Middle Aged | 19 | 2024 | 30812 | 0.180 |
Why?
| | Adrenalectomy | 1 | 2000 | 66 | 0.180 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 147 | 0.170 |
Why?
| | Tryptophan | 2 | 2014 | 171 | 0.170 |
Why?
| | Paraganglioma | 1 | 2021 | 49 | 0.170 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 179 | 0.170 |
Why?
| | Aged | 15 | 2024 | 21892 | 0.170 |
Why?
| | Male | 29 | 2024 | 62757 | 0.160 |
Why?
| | Animals | 20 | 2021 | 34487 | 0.160 |
Why?
| | Abdominal Injuries | 1 | 2000 | 117 | 0.160 |
Why?
| | Mice, Inbred C57BL | 8 | 2011 | 5268 | 0.160 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2019 | 34 | 0.150 |
Why?
| | Treatment Outcome | 6 | 2024 | 10110 | 0.150 |
Why?
| | Stress, Physiological | 1 | 2002 | 411 | 0.150 |
Why?
| | Trans-Activators | 1 | 2021 | 381 | 0.150 |
Why?
| | Myocytes, Cardiac | 1 | 2002 | 492 | 0.150 |
Why?
| | Mice | 15 | 2021 | 16574 | 0.150 |
Why?
| | Stem Cells | 1 | 2002 | 577 | 0.150 |
Why?
| | Pancreatectomy | 1 | 2000 | 241 | 0.150 |
Why?
| | Adrenal Cortex | 1 | 2018 | 27 | 0.150 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 258 | 0.140 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 33 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1343 | 0.140 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2018 | 60 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1558 | 0.130 |
Why?
| | Carcinoma | 1 | 2018 | 215 | 0.130 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 4 | 2004 | 83 | 0.130 |
Why?
| | Follow-Up Studies | 2 | 2024 | 4853 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 3 | 2021 | 875 | 0.130 |
Why?
| | Medical Oncology | 1 | 2018 | 271 | 0.130 |
Why?
| | Cytokines | 2 | 2015 | 1984 | 0.130 |
Why?
| | Antibodies | 3 | 2002 | 392 | 0.130 |
Why?
| | Adrenal Glands | 1 | 2016 | 70 | 0.130 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 76 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 430 | 0.120 |
Why?
| | Virus Latency | 1 | 2016 | 78 | 0.120 |
Why?
| | Sepsis | 1 | 2001 | 562 | 0.120 |
Why?
| | Retrospective Studies | 6 | 2024 | 14404 | 0.120 |
Why?
| | Multimodal Imaging | 1 | 2015 | 109 | 0.120 |
Why?
| | Female | 19 | 2024 | 68016 | 0.120 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2014 | 42 | 0.110 |
Why?
| | Islets of Langerhans | 1 | 2000 | 790 | 0.110 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 210 | 0.110 |
Why?
| | DNA, Viral | 1 | 2016 | 348 | 0.110 |
Why?
| | Elective Surgical Procedures | 2 | 2014 | 162 | 0.110 |
Why?
| | Carotid Artery Injuries | 2 | 2004 | 41 | 0.110 |
Why?
| | Tunica Intima | 2 | 2004 | 80 | 0.110 |
Why?
| | Subtraction Technique | 1 | 2013 | 23 | 0.100 |
Why?
| | Preoperative Care | 3 | 2024 | 335 | 0.100 |
Why?
| | Mice, Knockout | 7 | 2004 | 2757 | 0.100 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2015 | 366 | 0.100 |
Why?
| | Adult | 9 | 2024 | 35176 | 0.100 |
Why?
| | Chemokine CCL2 | 2 | 2011 | 117 | 0.100 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2015 | 734 | 0.100 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2016 | 840 | 0.100 |
Why?
| | Herpesvirus 3, Human | 1 | 2016 | 330 | 0.100 |
Why?
| | Apoptosis | 4 | 2021 | 2425 | 0.100 |
Why?
| | Carcinoma, Papillary | 1 | 2012 | 76 | 0.090 |
Why?
| | Sensitivity and Specificity | 4 | 2024 | 1813 | 0.090 |
Why?
| | Young Adult | 3 | 2024 | 12281 | 0.090 |
Why?
| | Cell Line, Tumor | 4 | 2021 | 3168 | 0.090 |
Why?
| | Radiopharmaceuticals | 1 | 2012 | 166 | 0.090 |
Why?
| | Vascular Surgical Procedures | 3 | 2004 | 294 | 0.090 |
Why?
| | Fluorescent Antibody Technique | 2 | 2002 | 370 | 0.090 |
Why?
| | Cell Proliferation | 4 | 2021 | 2337 | 0.090 |
Why?
| | Patient Care Management | 1 | 2011 | 56 | 0.090 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 176 | 0.090 |
Why?
| | Psychomotor Agitation | 1 | 2011 | 64 | 0.090 |
Why?
| | Acute Disease | 2 | 2011 | 961 | 0.080 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2010 | 67 | 0.080 |
Why?
| | Extracellular Space | 1 | 2010 | 119 | 0.080 |
Why?
| | Risk Assessment | 4 | 2024 | 3223 | 0.080 |
Why?
| | Calcium | 1 | 2015 | 1182 | 0.080 |
Why?
| | Endotoxins | 1 | 2010 | 215 | 0.080 |
Why?
| | Interleukin-6 | 2 | 2011 | 712 | 0.080 |
Why?
| | Adolescent | 3 | 2024 | 20158 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2015 | 1105 | 0.080 |
Why?
| | Clinical Trials as Topic | 3 | 2018 | 997 | 0.080 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 275 | 0.080 |
Why?
| | Intestinal Perforation | 1 | 2008 | 44 | 0.080 |
Why?
| | Duodenum | 1 | 2008 | 71 | 0.080 |
Why?
| | Disease Models, Animal | 3 | 2011 | 3936 | 0.080 |
Why?
| | Pancreatic Ducts | 1 | 2008 | 79 | 0.070 |
Why?
| | Wounds, Penetrating | 1 | 2008 | 63 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2010 | 347 | 0.070 |
Why?
| | Mutation | 4 | 2021 | 3682 | 0.070 |
Why?
| | Computer Simulation | 1 | 2011 | 936 | 0.070 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2008 | 217 | 0.070 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2008 | 206 | 0.070 |
Why?
| | Macrophages | 2 | 2011 | 1460 | 0.070 |
Why?
| | Software | 1 | 2011 | 606 | 0.060 |
Why?
| | Carotid Arteries | 2 | 2004 | 194 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2509 | 0.060 |
Why?
| | Hyperplasia | 2 | 2004 | 170 | 0.060 |
Why?
| | Cell Count | 2 | 2002 | 310 | 0.060 |
Why?
| | Biopsy, Fine-Needle | 2 | 2017 | 66 | 0.060 |
Why?
| | Time Factors | 5 | 2015 | 6479 | 0.060 |
Why?
| | Toll-Like Receptors | 2 | 2002 | 179 | 0.060 |
Why?
| | Coronary Disease | 2 | 2004 | 384 | 0.060 |
Why?
| | Transplantation | 1 | 2004 | 25 | 0.060 |
Why?
| | Vasculitis | 1 | 2004 | 59 | 0.060 |
Why?
| | Signal Transduction | 3 | 2016 | 4812 | 0.050 |
Why?
| | Insulinoma | 1 | 2003 | 30 | 0.050 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2004 | 139 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2018 | 1288 | 0.050 |
Why?
| | Computers | 1 | 2023 | 65 | 0.050 |
Why?
| | Parathyroid Neoplasms | 1 | 2002 | 13 | 0.050 |
Why?
| | Parathyroidectomy | 1 | 2002 | 7 | 0.050 |
Why?
| | Collateral Circulation | 1 | 2002 | 18 | 0.050 |
Why?
| | Cell Physiological Phenomena | 1 | 2002 | 20 | 0.050 |
Why?
| | Thyrotropin | 1 | 2023 | 109 | 0.050 |
Why?
| | Interleukin-11 | 1 | 2002 | 9 | 0.050 |
Why?
| | Neurosurgical Procedures | 1 | 2004 | 170 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2016 | 477 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2004 | 298 | 0.050 |
Why?
| | Vinblastine | 1 | 2002 | 68 | 0.050 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2002 | 11 | 0.050 |
Why?
| | Risk Factors | 5 | 2012 | 9696 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2015 | 608 | 0.050 |
Why?
| | Lung | 4 | 2002 | 3745 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2015 | 309 | 0.050 |
Why?
| | Endosonography | 1 | 2003 | 142 | 0.050 |
Why?
| | Receptors, Cytokine | 1 | 2002 | 35 | 0.050 |
Why?
| | Mitochondria, Heart | 1 | 2002 | 92 | 0.050 |
Why?
| | Hemostatics | 1 | 2002 | 47 | 0.050 |
Why?
| | Vasopressins | 1 | 2002 | 64 | 0.050 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1663 | 0.050 |
Why?
| | Organ Transplantation | 2 | 2001 | 218 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2002 | 165 | 0.050 |
Why?
| | Internship and Residency | 1 | 2011 | 1043 | 0.050 |
Why?
| | NF-kappa B | 4 | 2010 | 649 | 0.050 |
Why?
| | Oximes | 1 | 2021 | 20 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2002 | 185 | 0.050 |
Why?
| | Emergencies | 1 | 2001 | 154 | 0.040 |
Why?
| | Pressure | 1 | 2001 | 236 | 0.040 |
Why?
| | Indazoles | 1 | 2021 | 65 | 0.040 |
Why?
| | Adenoma | 1 | 2002 | 212 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1047 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2003 | 396 | 0.040 |
Why?
| | Neovascularization, Physiologic | 1 | 2001 | 172 | 0.040 |
Why?
| | Interleukins | 1 | 2002 | 240 | 0.040 |
Why?
| | Laparotomy | 1 | 2000 | 106 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 356 | 0.040 |
Why?
| | Cardiovascular System | 1 | 2001 | 136 | 0.040 |
Why?
| | Ultrasonography | 1 | 2024 | 708 | 0.040 |
Why?
| | Military Medicine | 1 | 2000 | 62 | 0.040 |
Why?
| | Myocardial Contraction | 1 | 2001 | 333 | 0.040 |
Why?
| | Imidazoles | 1 | 2021 | 228 | 0.040 |
Why?
| | Toll-Like Receptor 4 | 3 | 2010 | 263 | 0.040 |
Why?
| | Neovascularization, Pathologic | 1 | 2001 | 289 | 0.040 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2002 | 418 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 165 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 930 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 675 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 304 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2018 | 37 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 3 | 2004 | 42 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2002 | 475 | 0.040 |
Why?
| | Lamin Type B | 1 | 2018 | 7 | 0.040 |
Why?
| | NIMA-Related Kinases | 1 | 2018 | 8 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2000 | 264 | 0.040 |
Why?
| | Naphthyridines | 1 | 2018 | 16 | 0.040 |
Why?
| | Piperazines | 1 | 2021 | 332 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2019 | 257 | 0.040 |
Why?
| | Graft Rejection | 1 | 2002 | 557 | 0.040 |
Why?
| | Aged, 80 and over | 4 | 2016 | 7029 | 0.040 |
Why?
| | Interleukin-1 | 1 | 2002 | 949 | 0.040 |
Why?
| | Thyroid Gland | 1 | 2018 | 94 | 0.040 |
Why?
| | Homeostasis | 1 | 2002 | 605 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 809 | 0.040 |
Why?
| | Aldosterone | 1 | 2018 | 43 | 0.040 |
Why?
| | Ventricular Function, Left | 1 | 2001 | 524 | 0.040 |
Why?
| | Immunoblotting | 1 | 2018 | 301 | 0.040 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2002 | 311 | 0.040 |
Why?
| | Carcinoma, Medullary | 1 | 2017 | 14 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 323 | 0.030 |
Why?
| | Hemorrhage | 1 | 2001 | 643 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 138 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2000 | 860 | 0.030 |
Why?
| | Frozen Sections | 1 | 1996 | 25 | 0.030 |
Why?
| | Cardiac Surgical Procedures | 1 | 2002 | 493 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2015 | 3324 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 744 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2002 | 801 | 0.030 |
Why?
| | Laparoscopy | 1 | 2000 | 450 | 0.030 |
Why?
| | Cricoid Cartilage | 1 | 2015 | 13 | 0.030 |
Why?
| | Varicella Zoster Virus Infection | 1 | 2016 | 25 | 0.030 |
Why?
| | Prospective Studies | 3 | 2015 | 7035 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 95 | 0.030 |
Why?
| | Tracheostomy | 1 | 1997 | 119 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 83 | 0.030 |
Why?
| | Taxoids | 1 | 2015 | 95 | 0.030 |
Why?
| | Carboplatin | 1 | 2015 | 140 | 0.030 |
Why?
| | Herpes Simplex | 1 | 2016 | 93 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2015 | 29 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 879 | 0.030 |
Why?
| | Lung Diseases | 1 | 2001 | 713 | 0.030 |
Why?
| | Herpesvirus 1, Human | 1 | 2016 | 87 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2015 | 150 | 0.030 |
Why?
| | Disease Progression | 1 | 2002 | 2598 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 741 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 632 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2002 | 2703 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 578 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2015 | 216 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 128 | 0.030 |
Why?
| | Anilides | 1 | 2014 | 73 | 0.030 |
Why?
| | Paclitaxel | 1 | 2015 | 213 | 0.030 |
Why?
| | Niacinamide | 1 | 2014 | 73 | 0.030 |
Why?
| | Phenylurea Compounds | 1 | 2014 | 89 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 283 | 0.030 |
Why?
| | Doxorubicin | 1 | 2015 | 322 | 0.030 |
Why?
| | Melatonin | 1 | 2014 | 120 | 0.030 |
Why?
| | Radioactive Tracers | 1 | 2013 | 3 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1408 | 0.030 |
Why?
| | Incidence | 2 | 2011 | 2614 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1020 | 0.030 |
Why?
| | Cell Movement | 3 | 2001 | 933 | 0.030 |
Why?
| | Mice, Inbred Strains | 2 | 2004 | 402 | 0.030 |
Why?
| | Postoperative Care | 1 | 2014 | 235 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2014 | 260 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 409 | 0.020 |
Why?
| | Preoperative Period | 1 | 2012 | 113 | 0.020 |
Why?
| | Serotonin | 1 | 2014 | 317 | 0.020 |
Why?
| | Inflammation | 1 | 2003 | 2646 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 993 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 940 | 0.020 |
Why?
| | Pyridines | 1 | 2014 | 474 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 317 | 0.020 |
Why?
| | Intraoperative Period | 2 | 2003 | 53 | 0.020 |
Why?
| | Efficiency | 1 | 2011 | 91 | 0.020 |
Why?
| | Linear Models | 1 | 2012 | 816 | 0.020 |
Why?
| | Heart Function Tests | 1 | 2010 | 59 | 0.020 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 253 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2002 | 1994 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2002 | 815 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2859 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2014 | 1852 | 0.020 |
Why?
| | Workload | 1 | 2011 | 150 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2012 | 465 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2014 | 734 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2011 | 205 | 0.020 |
Why?
| | Safety | 1 | 2011 | 328 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1492 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1043 | 0.020 |
Why?
| | Rupture | 1 | 2008 | 88 | 0.020 |
Why?
| | Bile Ducts | 1 | 2008 | 67 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1140 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1266 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 1096 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1262 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 301 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 1975 | 0.020 |
Why?
| | Neoplasms | 1 | 2002 | 2460 | 0.020 |
Why?
| | Cattle | 1 | 2010 | 962 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 511 | 0.020 |
Why?
| | Patient Readmission | 1 | 2012 | 663 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 3039 | 0.020 |
Why?
| | Patient Care Team | 1 | 2011 | 597 | 0.020 |
Why?
| | Growth Substances | 1 | 2004 | 150 | 0.010 |
Why?
| | Survival Rate | 1 | 2008 | 1870 | 0.010 |
Why?
| | Protein Binding | 1 | 2010 | 2105 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3100 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3009 | 0.010 |
Why?
| | DNA | 1 | 2010 | 1392 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 2003 | 88 | 0.010 |
Why?
| | Monokines | 1 | 2002 | 22 | 0.010 |
Why?
| | Chemokine CXCL2 | 1 | 2002 | 43 | 0.010 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2002 | 85 | 0.010 |
Why?
| | Transcription Factor RelA | 1 | 2002 | 79 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2002 | 273 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2001 | 65 | 0.010 |
Why?
| | Endothelial Growth Factors | 1 | 2001 | 51 | 0.010 |
Why?
| | Peroxidase | 1 | 2002 | 169 | 0.010 |
Why?
| | United States | 1 | 2018 | 13785 | 0.010 |
Why?
| | Lymphokines | 1 | 2001 | 115 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2002 | 112 | 0.010 |
Why?
| | Wounds, Nonpenetrating | 1 | 2004 | 271 | 0.010 |
Why?
| | Interleukin-8 | 1 | 2002 | 258 | 0.010 |
Why?
| | Permeability | 1 | 2001 | 156 | 0.010 |
Why?
| | Surgery, Plastic | 1 | 2001 | 33 | 0.010 |
Why?
| | Postoperative Period | 1 | 2002 | 322 | 0.010 |
Why?
| | Protein Transport | 1 | 2002 | 420 | 0.010 |
Why?
| | Cohort Studies | 1 | 2011 | 5378 | 0.010 |
Why?
| | Trachea | 1 | 2002 | 221 | 0.010 |
Why?
| | Cell Division | 1 | 2002 | 777 | 0.010 |
Why?
| | Aorta | 1 | 2002 | 408 | 0.010 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2002 | 224 | 0.010 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 365 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2002 | 624 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2001 | 499 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2011 | 5353 | 0.010 |
Why?
| | Colorado | 1 | 2008 | 4369 | 0.010 |
Why?
| | Escherichia coli | 1 | 2002 | 766 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 1943 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1996 | 170 | 0.010 |
Why?
| | Gene Expression | 1 | 2001 | 1454 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 200 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 1996 | 187 | 0.010 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 1997 | 169 | 0.010 |
Why?
| | Coronary Artery Disease | 1 | 2001 | 675 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2002 | 2669 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2002 | 4006 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 1996 | 567 | 0.010 |
Why?
|
|
Raeburn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|